Ibrutinib for rituximab-refractory Waldenström macro-globulinemia

Maria Gavriatopoulou; Efstathios Kastritis; Meletios A Dimopoulos

doi:10.18632/oncotarget.23400

Related publications

Article2021

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial

Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios A Dimopoulos

Article2018

Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.

Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, David MacDonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Maria Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske

Article2018

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, D. Blair Macdonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Lorella Orsucci, M. Lia Palomba, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske

Article2016

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T. Heffner, Chaim Shustik, Ramón García‐Sánz, Robert F. Cornell, Carlos Fernández de Larrea, Jorge J. Castillo, Miquel Granell, Marie‐Christine Kyrtsonis, Véronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh,

Article2018

Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)

M. Lia Palomba, Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García‐Sánz, David MacDonald, Véronique Leblond, Beatrice Mahé, Charles Herbaux, Constantine S. Tam, Jeffrey Matous, Chaim Shustik, Efstathios Kastritis, Steven P. Treon, Jianling Li, Zeena Salman, Thorsten Graef, Christian Buske

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia

Discussion(0)

Related publications

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial

Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Ibrutinib/Rituximab versus Placebo/Rituximab: A Randomized, Phase 3 Trial in Waldenström’s Macroglobulinemia (iNNOVATE)